Diagnostic biomarkers in non-muscle invasive bladder cancer
Diagnostic biomarkers in non-muscle invasive bladder cancer
复制标题
DOI：
10.1007/s00345-018-2567-1
复制
发表时间：
2019-10-01
影响因子：
3.4
通讯作者：
Furuya, Hideki
中科院分区：
文献类型：
--
作者：
Faiena, Izak;Rosser, Charles J.;Furuya, Hideki
非肌层浸润性膀胱癌（NMIBC）的成功治疗在很大程度上依赖于我们准确检测疾病的能力，通常是在血尿的存在下，以及在有NMIBC病史的患者中检测早期复发肿瘤。不幸的是，目前NMIBC的生物标志物景观是一项正在进行的工作。膀胱镜检查仍然是金标准，但仍然可以错过10%的肿瘤。因此，医生经常使用其他工具来帮助诊断膀胱癌，如尿细胞学。尿细胞学检查是高级别疾病的一个很好的选择;然而，它受到检测低级别疾病的低灵敏度以及细胞病理学家之间的可变解释的限制。因此，膀胱镜检查和尿细胞学检查的局限性已经揭示了对更稳健的诊断测定的需求。在这篇非系统性综述中，我们讨论了这些测试的性能，潜在的优点或缺点，以及NMIBC生物标志物的未来发展方向。
Successful treatment of non-muscle invasive bladder cancer (NMIBC) relies heavily on our ability to accurately detect disease typically in the presence of hematuria as well as to detect the early recurrent tumors in patients with a history of NMIBC. Unfortunately, the current biomarker landscape for NMIBC is a work in progress. Cystoscopy continues to be the gold standard, but can still miss 10% of tumors. Therefore, physicians frequently use additional tools to aid in the diagnosis of bladder cancer, such as urinary cytology. The urinary cytology is a good option for high-grade disease; however, it is limited by low sensitivity in detecting low-grade disease, as well as variable interpretation among cytopathologists. Thus, the limitations of cystoscopy and urinary cytology have brought to light the need for more robust diagnostic assays. In this non-systematic review, we discuss the performance, potential advantages or disadvantages of these tests, and the future direction of biomarkers in NMIBC.